Valeant Pharmaceuticals (VRX - option chain) stock is trading lower today after an article in Barron's (subscription required) over the weekend said the company could see trouble ahead if its experimental epilepsy drug, which is undergoing the regulatory review process, is not profitable enough to offset declining royalties from its hepatitis C treatment. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on VRX.This morning, VRX opened at $32.15. So far today the stock has hit a high of $32.95 and a low of $31.88. As of 11:30, VRX is trading at $32.07, down $1.21 (-3.6%). The chart for VRX looks bullish.
For a bearish hedged play on this stock, I would consider a January bear-call credit spread above the $35 range. A bear-call credit spread is an options position that combines the purchase and sale of call options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make an 11.1% return in two months as long as VRX is below $35 at January expiration. Valeant would have to rise by more than 9% before we would start to lose money. Learn more about this type of trade here.
VRX hasn't been above $35 at all since 2001 and has shown resistance around $34.50 recently.
Brent Archer is an options analyst and writer at Investors Observer.
DISCLOSURE: Mr. Archer owns and/or controls diversified portfolios of long and short stock and option positions that may include holdings in companies he writes about. At publication time, Brent neither owns nor controls positions in VRX.
Closing Bell: When We All Love the PIIGS (NBG, SQNM, PG, ERTS, KO)
Serious Money: Cheapest Stocks List Shrinks from 26 to 21
Chasing Value: Hasbro Earnings Makes My Point
Add your comments